Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes

Bente K. Kilhovd, I. Giardino, P. A. Torjesen, K. I. Birkeland, T. J. Berg, P. J. Thornalley, M. Brownlee, K. F. Hanssen

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nα-acetyl-Nδ-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 ± 6.1 (mean ± SD) years and with duration of diabetes of 7.3 ± 3.1 years, and in 19 nondiabetic controls aged 56.3 ± 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P = .0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P < .0001), and r = 0.65 for controls (P = .002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and Nε-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P = .02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A1c (HbA1c) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds.

Original languageEnglish (US)
Pages (from-to)163-167
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Pyruvaldehyde
Type 2 Diabetes Mellitus
Serum
Immune Sera
Europium
Advanced Glycosylation End Products
Bovine Serum Albumin
imidazolone
Immunoassay
Anti-Idiotypic Antibodies
Fasting
Hemoglobins
Proteins
Fluorescence
Glucose

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Kilhovd, B. K., Giardino, I., Torjesen, P. A., Birkeland, K. I., Berg, T. J., Thornalley, P. J., ... Hanssen, K. F. (2003). Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 52(2), 163-167. https://doi.org/10.1053/meta.2003.50035

Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. / Kilhovd, Bente K.; Giardino, I.; Torjesen, P. A.; Birkeland, K. I.; Berg, T. J.; Thornalley, P. J.; Brownlee, M.; Hanssen, K. F.

In: Metabolism: Clinical and Experimental, Vol. 52, No. 2, 01.02.2003, p. 163-167.

Research output: Contribution to journalArticle

Kilhovd, BK, Giardino, I, Torjesen, PA, Birkeland, KI, Berg, TJ, Thornalley, PJ, Brownlee, M & Hanssen, KF 2003, 'Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes', Metabolism: Clinical and Experimental, vol. 52, no. 2, pp. 163-167. https://doi.org/10.1053/meta.2003.50035
Kilhovd, Bente K. ; Giardino, I. ; Torjesen, P. A. ; Birkeland, K. I. ; Berg, T. J. ; Thornalley, P. J. ; Brownlee, M. ; Hanssen, K. F. / Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. In: Metabolism: Clinical and Experimental. 2003 ; Vol. 52, No. 2. pp. 163-167.
@article{23e81364d3b14f5db12642671a00c1ea,
title = "Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes",
abstract = "A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nα-acetyl-Nδ-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 ± 6.1 (mean ± SD) years and with duration of diabetes of 7.3 ± 3.1 years, and in 19 nondiabetic controls aged 56.3 ± 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P = .0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P < .0001), and r = 0.65 for controls (P = .002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and Nε-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P = .02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A1c (HbA1c) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds.",
author = "Kilhovd, {Bente K.} and I. Giardino and Torjesen, {P. A.} and Birkeland, {K. I.} and Berg, {T. J.} and Thornalley, {P. J.} and M. Brownlee and Hanssen, {K. F.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1053/meta.2003.50035",
language = "English (US)",
volume = "52",
pages = "163--167",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes

AU - Kilhovd, Bente K.

AU - Giardino, I.

AU - Torjesen, P. A.

AU - Birkeland, K. I.

AU - Berg, T. J.

AU - Thornalley, P. J.

AU - Brownlee, M.

AU - Hanssen, K. F.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nα-acetyl-Nδ-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 ± 6.1 (mean ± SD) years and with duration of diabetes of 7.3 ± 3.1 years, and in 19 nondiabetic controls aged 56.3 ± 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P = .0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P < .0001), and r = 0.65 for controls (P = .002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and Nε-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P = .02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A1c (HbA1c) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds.

AB - A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nα-acetyl-Nδ-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 ± 6.1 (mean ± SD) years and with duration of diabetes of 7.3 ± 3.1 years, and in 19 nondiabetic controls aged 56.3 ± 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P = .0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P < .0001), and r = 0.65 for controls (P = .002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and Nε-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P = .02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A1c (HbA1c) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds.

UR - http://www.scopus.com/inward/record.url?scp=0037302018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037302018&partnerID=8YFLogxK

U2 - 10.1053/meta.2003.50035

DO - 10.1053/meta.2003.50035

M3 - Article

C2 - 12601626

AN - SCOPUS:0037302018

VL - 52

SP - 163

EP - 167

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 2

ER -